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Lung involvement accounts for significant morbidity and is a leading cause of mortality in patients with 
systemic sclerosis (SSc). It has been shown that different patterns of pulmonary involvement are seen in 
different subtypes of SSc. This paper reports a retrospective review of 72 patients with SSc to determine 
whether disease classification according to the extent of skin involvement alone (diffuse vs. limited) or 
autoantibody status was predictive of pulmonary parenchymal involvement. The diagnosis of interstitial lung 
disease was based on pulmonary function tests and chest radiographs. Restrictive lung disease was common 
in both limited SSc (1SSc) and diffuse SSc (dSSc), occurring in 30% and 50% of these patients respectively 
(PzO.16). Radiographic evidence of significant interstitial disease was also comparable between the groups 
[nine of 32 1SSc patients (28%) vs. six of 17 dSSc patients (32%), P=n.s.]. No significant difference in mean 
lung function was found between patients with anti-SC1 70 antibody (n = 12) compared to those without (n = 60) 
(TLC 79.0 & SE 51% predicted vs. 82.8 f 2.2, P=n.s.; DLCO 63.0 f 5.1 vs. 59.7 & 2.5, P=n.s.). By contrast, 
statistically significant differences in mean lung function were found between patients with anticentromere 
antibody (ACA) (n=24) and those without ACA (n=48) (TLC 98.6 + SE 3.9% predicted vs. 79.7 f 3.1%, 
P<O.OOl); and less frequent radiographic evidence of severe interstitial disease (0 of 17 with significant 
interstitial changes on chest radiograph vs. 15 of 32 (47%), P=O.O02). It is concluded that classification of SSc 
patients on the basis of the distribution of skin involvement poorly predicts the occurrence of interstitial lung 
disease. On the other hand, ACA is highly associated with the absence of interstitial lung disease. 
Introduction 
Systemic sclerosis (scleroderma, SSc) is a connec- 
tive tissue disorder of unknown etiology with hetero- 
geneous manifestations involving skin, peripheral 
vasculature, heart, kidneys, gastrointestinal tract and 
lungs. Lung involvement is a major cause of morbid- 
ity and a leading cause of death in SSc patients (l-3). 
Autopsy studies have shown that as many as 79% 
have interstitial lung disease, while 29% have pulmo- 
nary vascular disease (4). Because of the heterogene- 
ity of lung involvement in SSc patients, there has 
been great interest in clinical markers of disease 
which could predict patterns of organ involvement. 
Previous reports have suggested a relation between 
pulmonary parenchymal or vascular involvement and 
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other clinical features of the disease, such as extent of 
skin involvement and Raynaud’s phenomenon (5-7). 
For example, patients with the CREST syndrome 
(having clinical or radiologic evidence of calcinosis, 
Raynaud’s, esophageal dysmotility, sclerodactyly, 
and telangiectasia) variant of SSc appear less likely to 
have restrictive pulmonary disease but have a higher 
frequency of isolated pulmonary vascular disease (5). 
The presence of specific autoantibodies, especially 
anticentromere (ACA) or anti-SC1 70 (antibodies to 
topoisomerase I, a nucleoprotein) (8-12) have also 
been shown to correlate with the presence of pul- 
monary parenchymal and vascular abnormalities in 
SSc patients. Antinuclear autoantibodies (ANA) are 
detected in virtually all patients with SSc (13). Two 
specific autoantibodies, anticentromere and anti-SC1 
70, occur in approximately 22% and 26% of patients, 
respectively (8). Although these antibodies usually do 
not occur together, rare cases demonstrating the 
presence of both antibodies have been reported 
(14,15). It has been suggested that interstitial lung 
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disease is less frequent in SSc patients with ACA than 
those without this antibody, but this has not been 
confirmed (8,lO). Furthermore, single-breath carbon 
monoxide diffusing capacity (DLCO) has been shown 
to be lower in SSc patients with anti-SC1 70 antibodies 
than in patients without anti-SC1 70, suggesting a 
greater incidence of interstitial disease in this 
group (9). 
A recently proposed system for classifying SSc 
identifies patients on the basis of extent of skin 
involvement as compared to other clinical features 
such as calcinosis, Raynaud’s phenomenon, esopha- 
geal dysmotility, sclerodactyly and the presence of 
telangiectasias (16). Skin involvement appears as 
scarring (fibrosis) and skin thickening which gives 
the skin a hidebound appearance. Skin involve- 
ment limited to the distal extremities (below the 
elbow or knee) or the head and neck is classified as 
limited systemic sclerosis (1SSc). Skin involvement 
extending to the trunk (shoulders, chest, back, abdo- 
men) or proximal extremities is classified as diffuse 
systemic sclerosis (dSSc). The latter has been 
reported to be associated with a more aggressive 
clinical course of disease and with a greater risk of 
visceral complications than 1SSc patients (8,17). 
This study was undertaken to determine whether 
classification of SSc patients on the basis of the extent 
of skin involvement or on the basis of autoantibody 
status was more predictive of interstitial lung involve- 
ment. The ability to predict which SSc patients are 
likely to develop pulmonary involvement would 
greatly enhance efforts to plan early therapeutic 
intervention in this disease. 
Methods 
PATIENTS 
Seventy-two patients who were evaluated consecu- 
tively at the Thomas Jefferson University Sclero- 
derma Center during 1990 to 1992 were included. 
Each patient satisfied the American College of 
Rheumatology criteria for SSc (18). Patients were 
classified as having either limited or diffuse SSc based 
on extent of skin involvement (16). Patients with skin 
involvement confined to the face, hands, forearms, or 
lower legs were classified as having 1SSc. Patients 
with skin involvement of the trunk or proximal 
extremities (proximal to the elbow or knee) were 
classified as having dSSc. 
AUTOANTIBODY DETERMINATION 
Dilutions of serum from patients were applied 
to commercially prepared HEp-2 cells, followed 
by FITC antihuman immunoglobulin (Cooper, 
Malvern, PA) using methods previously described 
(19,20). Anticentromere antibodies were detected by 
the characteristic fluorescent ANA pattern (large 
granules dispersed throughout the nucleus of inter- 
phase cells segregating with condensed chromosomes 
in mitotic cells). A titre of less than or equal to 1:40 
was considered negative. Antibodies to Scl-70 were 
identified using rabbit thymus extract (RTE), pre- 
pared by resuspension of a commercially prepared 
thymus extract (Zeus Wampole) in phosphate buff- 
ered saline. A titre of less than or equal to 1:40 was 
considered negative. Antibodies were detected by 
double immunodiffusion against RTE and compared 
to sera with known specificity to topoisomerase I. 
PULMONARY FUNCTION TESTINGS 
Spirometry, lung volumes and DLCO were per- 
formed using standardized techniques as described by 
the American Thoracic Society (21) and expressed as 
percent of predicted normal. A Collins DSl (Walter 
E. Collins, Co, Braintree, Massachusetts) multi-lung 
analyser was used to measure forced vital capacity 
(FVC), forced expired volume at 1 s (FEV,), total 
lung capacity (TLC), and DLCO in each patient. 
Total lung capacity was measured by closed circuit 
helium equilibration technique. Predicted normals 
were obtained from published standards (22-24). 
Patients were considered to have a restrictive ventila- 
tory impairment if TLC was ~80% of predicted 
normals. 
CHEST RADIOGRAPHS 
Chest radiographs (standard postero-anterior, and 
lateral views) were read jointly by two experienced 
observers (EFC, PWS) who were unaware of the 
clinical and serologic features of each patient. The 
distribution of pulmonary parenchymal abnormality 
was divided by side (right and left) and by zone 
(upper, middle and lower). The profusion of abnor- 
mality in each zone was graded on a O-3 scale 
(absent, minimal, moderate and extensive). Profu- 
sion, zonal distribution, and symmetry were com- 
bined to produce three categories of radiologic 
parenchymal abnormalities: A, normal or no signifi- 
cant parenchymal abnormality (all zones graded 0 or 
a solitary zone graded no higher than 1); B, minimal 
abnormality of unknown significance (one bilaterally 
symmetric zone pair graded no higher than 1); C, 
significant interstitial abnormality (any involvement 
exceeding categories A and B). 
STATISTICAL ANALYSES 
Mean values for pulmonary function as percent 
predicted normals were compared using one way 
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Table I Clinical and demographic characteristics of limited and diffuse systemic sclerosis 
patients 
Limited SSc Diffuse SSc 
ACA’ ACA - SC1 70+ SC1 70 
(n=21) (n=25) (n=lO) (n= 16) 
Age (years) 
Female (%) 
Disease duration (yrs) 
from first symptom 
from first non-Raynaud symptom 
Smoking history* 
Anti-fibrotic therapy? 
CREST by clinic evaluation 
58.6 54.5 43.1 49.0 
21 (loo%): 19 (76%) S(SO%) 14(88%) 
13.9 9.7 6.5 6.1 
10.6 6.2 5.6 5.6 
8/21 15125 418 12116 
3/21 7125 9110 9116 
15/21 12125 o/10 3116 
SSc, systemic sclerosis; ACA, anticentromere antibody; Scl70, anti-SC1 70 antibody; *defined as 
current smoker or ex-smoker with greater than 10 pack-years; TD-penicillamine (for 6 months) 
or, in two patients, extracorporeal photochemotherapy (both diffuse SSc, Scl 70 negative); 
IWhen compared to ACA - 1SSc there were significantly more females in the ACA + group. 
analysis of variance (ANOVA) (25). The frequency of 
radiographic abnormalities was compared using a 
proportional model. P values of less than 0.05 were 
considered statistically significant. P values of greater 
than 0.20 are reported as not significant. 
Results 
The demographic features of the patients are 
shown in Table 1. Forty-six patients were classified as 
having 1SSc on the basis of extent of skin involve- 
ment; 26 patients had dSSc. The mean age was 53 
years (range 20-77 years), and 84% were female. The 
average duration of SSc from the first non-Raynaud 
symptom was 7.6 years at the time of evaluation. 
Thirty-six (50%) patients had ACA or anti-SC1 70 
antibodies, although no patient had both ACA and 
anti-SC1 70 detected concurrently (Table 2). Anticen- 
tromere antibody was more common in 1SSc patients, 
and anti-SC1 70 was more common in dSSc patients. 
However, these antibodies did not occur exclusively 
in either group. Among 1SSc patients, 45.7% had 
ACA, and 38.5% of dSSc patients had anti-SC1 70 
antibody. These antibodies were somewhat specific; 
as the positive predictive value of ACA for 1SSc was 
87.5%, while anti-SC1 70 had a predictive value of 
83% for dSSc. Subgroups based on ACA status did 
not correspond with the presence of CREST syn- 
drome features (all five features present by history, 
examination or radiograph) (Table 1). The use of 
disease modifying anti-fibrotic therapy is also noted 
in Table 1. Except for the use of extracorporeal 
photochemotherapy in two dSSc patients, only 
D-penicillamine was used. 
Table 2 Autoantibodies in systemic sclerosis patients 
Antibody 
Limited SSc 
(n=46) 
Diffuse SSc 
(n=26) 
ACA+ 
Anti-SC1 70+ 
Neither 
21 (45.7%) 3 (11.5%) 
2 (4.3%) 10 (38.5%) 
23 (50%) 13 (50%) 
SSc, systemic sclerosis; ACA, anti-centromere antibody; 
Anti-SC1 70, anti-SC1 70 antibody. 
PULMONARY FUNCTION 
The frequency of restrictive lung disease did not 
differ significantly between 1SSc and dSSc patients 
[14/46 vs. 13/26 patients, P=O.16 (n.s.)] as shown in 
Table 3. In addition, there was no significant differ- 
ence between 1SSc and dSSc patients in the frequency 
of normal pulmonary function (15/46 vs. 5/26, 
P=n.s.), or isolated reduction in the DLCO (17/46 vs. 
8/26, P=n.s.). 
Pulmonary function according to autoantibody 
status is presented in Figs 1 and 2. There were no 
significant differences in mean lung function in 
patients with and without anti-SC1 70 antibody (Fig. 
l), but there was a trend toward a lower FVC in 
those with anti-SC1 70. Additionally, although more 
patients with anti-SC1 70 had restriction, this differ- 
ence was not significant (Table 4, PzO.19). However, 
patients with anti-SC1 70 antibody were more fre- 
quently treated with anti-fibrotic agents (83% vs. 
30%, P=O.O02). 
On the other hand, patients with ACA had pre- 
served lung volumes and higher DLCO (Fig. 2). 
In fact, only three of 24 patients with ACA had 
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Table 3 Primary patterns of pulmonary function abnor- 
malities in according to skin classification 
Limited SSc Diffuse SSc 
(n=46) (n=26) P value 
Normal* 15 (33%) 5 (19%) n.s. 
Isolated reduction 
in DLCOt 17 (37%) 8 (31%) n.s. 
Restriction1 14 (30%) 13 (50%) P=O.15 
SSc, systemic sclerosis. *Normal defined as FVC, and FEV, 
2 80%, TLC 2 80%, with DLCO 270% predicted normal. 
TIsolated reduction in DLCO defined as normal except for 
DLCO <75% predicted. SRestricted defined as FVC ~80% 
confirmed by TLC ~80% predicted, with or without reduc- 
tion in DrCO. 
P = 0.14 P = n.s. 
P = n.s. 
E a 60 - 
& 50 - 
40 - 
TLC FVC FEV, DLCO 
Fig I Pulmonary function in systemic sclerosis patients 
according to the presence (solid bar, n=12) or absence 
(open bar, n=60) of anti-SC1 70 antibodies. Values are 
means f SEM of percent predicted normal. 
120 
-3 
llo P<O.OOl P = 0.002 P<O.OOl 
FVC FEV, 
1 P=O.O09 I 
I 
DLCO 
Fig. 2 Pulmonary function in systemic sclerosis patients 
according to the presence (solid bar, n=24) or absence 
(open bar, n=48) of anticentromere antibodies. Values are 
means f SEM of percent predicted normal. 
restriction of lung volumes (defined as TLC ~80% 
predicted). Patients without ACA had reduced TLC 
and FVC values, indicating a significant restrictive 
impairment. For patients without ACA, 24 of 48 
(50%) had restriction (Table 4). Patients with ACA 
frequently had preserved lung volumes with an 
isolated reduction in DLCO (12/24 patients, 50%). 
Airways obstruction (defined as FEV,/FVC 
< 72%) was noted in both 1SSc and dSSc groups: nine 
of 46 (20%) 1SSc patients vs. three of 26 (12%) dSSc 
patients. There was no difference in the frequency of 
airways obstruction in patients with ACA compared 
to those without ACA (12.5% vs. 17%, P=n.s.) or in 
patients with and without anti-SC1 70 (10% vs. 12.5%, 
P>O.20). Nearly all patients in the present study 
population with evidence of large airways obstruc- 
tion were current or former smokers with greater 
than 10 pack-years of exposure to tobacco (83%). 
RADIOGRAPHY 
Thirty-two of 46 1SSc patients and 17 of 26 dSSc 
patients had radiographs available for review. Over- 
all, the frequency of significant interstitial abnormali- 
ties (category C) was comparable between 1SSc and 
dSSc patients (28% vs. 35%, P>O.20) (Table 5). There 
were no significant differences in the presence of 
radiographic abnormalities, as indicated by an 
increase in interstitial markings, between patients 
with and without anti-SC1 70 autoantibodies (Table 
6). Radiographic evidence of interstitial pulmonary 
disease was, however, less frequent and less extensive 
in patients with ACA when compared to those 
without ACA (6% vs. 47%, P<O.O02). 
Among patients with interstitial abnormalities 
(n=22), 50% had diffuse disease with lower lobe 
predominance, 27% had isolated lower lobe involve- 
ment, 9% had diffuse disease without any predomi- 
nant zonal involvement, and 14% had isolated mid or 
upper lung zone involvement. 
Eight-five percent of patients who had insignifi- 
cant or no radiographic interstitial abnormalities 
(Category A) had normal lung volumes, whereas four 
had minimally reduced lung volumes (TLC 65-80% 
predicted). Fifty-seven percent of patients with mini- 
mal interstitial abnormalities of uncertain signifi- 
cance (category B) had evidence of restriction with 
TLC of 73.5% predicted. The remaining patients with 
minimal interstitial abnormalities had normal lung 
volumes. Seventy-three percent of patients with sig- 
nificant interstitial abnormalities (category C) on 
chest radiograph had evidence of restrictive lung 
disease with mean TLC of 59.3% and mean DLCO of 
39.5% predicted. 
SPECIAL PATIENT GROUPS 
Among dSSc patients with ACA (three patients, 
who all lacked anti-SC1 70 antibody), only one had 
evidence of restrictive lung disease. This patient 
initially presented with limited disease but progressed 
to diffuse skin involvement with moderate interstitial 
lung disease (present by chest radiograph and 
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Table 4 Patterns of pulmonary function in systemic sclerosis 
According to ACA According to Scl 70 
ACA+ ACA SC1 70’ SC1 70 - 
(n=24) (?l=48) P value (n= 12) (n=60) P value 
Normal* 9 (37.5%) 11 (23%) n.s. 2 (16%) 18 (30%) n.s. 
Isolated reduction 
in DLCOt 12 (50%) 13 (27%) 0.095 3 (25%) 22 (37%) n.s. 
RestrictionS 3 (12.5%) 24 (50%) <0.005 7 (58.3%) 20 (33%) 0.19 
ACA, anticentromere antibody; Scl 70, anti-SC1 70 antibody. *Normal defined as FVC and 
FEV, 2 80%; TLC 2 80%; with DLCO 2 70% predicted normal. YIsolated reduction in DLCO 
defined as normal except for DLCO ~70% predicted. SRestriction defined as FVC ~80% 
confirmed by TLC ~80% predicted, with or without reduction in DLCO. 
Note: In the limited SSc group, 9146 (20%) patients had evidence of large airway obstruction 
with FEV,/FVC 272%. In the diffuse SSc group, 3/26 (12%) had evidence of large airways 
obstruction. 
Table 5 Interstitial abnormalities on chest radiograph according to skin classification 
Limited SSc Diffuse SSc 
(n=32) (n= 17) P value 
No radiographic abnormalities or 18 (56%) 9 (53%) n.s. 
radiographically insignificant abnormalities 
(see Methods) 
Minimal interstitial radiographic 5 (16%) 2 (12%) n.s. 
abnormalities of uncertain significance 
Significant interstitial 9 (28%) 6 (35%) n.s. 
radiographic abnormalities 
ACA, anticentromere antibody; Scl 70, anti-SC1 70 antibody. 
Table 6 Interstitial abnormalities on chest radiograph according to antibody status 
ACAi ACA 
(n= 17) (n=32) P value 
SC1 70’ 
(n=8) 
SC1 70 - 
(n=41) P value 
No radiographic 
abnormalities or 
radiographically 
insignificant 
abnormalities 
Minimal 
Significant 
16 (94%) 11 (34%) <O.OOl 4 (50%) 23 (56%) n.s. 
1 (6%) 6 (19%) =0.012 1 (12%) 6 (15%) n.s. 
0 (0%) 15 (47%) = 0.002 3 (38%) 12 (29%) n.s. 
ACA, anticentromere antibody; Scl 70, anti-SC1 70 antibody. 
confirmed at post-mortem examination) and severe Discussion 
pulmonary hypertension. The remaining two patients 
lacked evidence of interstitial lung disease by chest This study was undertaken to determine whether 
radiograph. Among 1SSc patients with anti-SC1 70 classification of SSc patients according to the extent 
antibody (two patients, who lacked ACA), both of skin involvement could predict the presence or 
had restrictive lung disease by pulmonary function absence of pulmonary involvement and restrictive 
criteria (chest radiographs were not available). lung disease. The present data indicate that 
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classification according to skin involvement alone is 
only weakly predictive of restrictive lung disease, as 
14/46 (30%) 1SSc patients had restriction compared to 
13/26 (50%) of dSSc patients. Thus, restrictive lung 
disease is common in both 1SSc and dSSc patients. 
This study’s definition of restrictive lung disease was 
arbitrary (TLC <80% predicted), it was believed to 
conservatively identify patients with pulmonary 
parenchymal abnormalities and it was applied con- 
sistently between all groups. Moreover, there was a 
correspondence between the pulmonary function 
abnormalities and radiographic abnormalities, as 
only four of 27 patients with normal chest radio- 
graphs had reduced TLC values and only seven of 30 
patients with normal TLC values had abnormal 
radiographs. 
A notable finding in this study was the observation 
that restrictive disease occurred infrequently in 
patients with ACA (3/24, 12.5%). In contrast, among 
patients without ACA, restriction was common, 
occurring in 24 of 48 patients (50%). The lower 
frequency of interstitial disease based on measure- 
ments of FEV, FVC and chest radiographs in 
patients with ACA has previously been noted (8-10). 
The present study supports and extends these obser- 
vations insofar as the evaluation of ILD included 
measurement of static lung volumes (TLC) and 
DLCO together with a blinded analysis of chest 
radiographs (observers unaware of clinical and sero- 
logic features of each patient). Additional studies are 
necessary to determine whether patients with ACA 
are ‘protected’ against the development of interstitial 
involvement, or if such involvement is mild and not 
detected by routine pulmonary function testing and 
chest radiography. 
Whereas ACA was almost exclusively identified in 
1SSc patients, a statistically significant difference in 
the frequency of restrictive lung disease between 1SSc 
and dSSc might be expected if greater numbers of 
patients were studied. Nevertheless, the occurrence 
of restrictive lung disease appears to be unrelated to 
the pattern of skin involvement; rather the presence 
of ACA appears to be associated with the absence of 
restrictive lung disease. The demonstration of a mod- 
erately reduced DLCO in ACA positive patients may 
indicate early pulmonary vascular disease, as others 
have suggested (5). The finding of infrequent restric- 
tion among patients with ACA is not attributable to 
the frequency of CREST syndrome features, as those 
features were frequently present in limited SSc 
patients with and without ACA. 
Patients with dSSc who have ACA (only three of 
72 patients in the present study) represent a rare 
population. Two of the three patients with this 
pattern lacked physiologic or radiographic evidence 
of interstitial lung disease. Thus ACA appears to be 
protective in dSSc as well. Limited SSc patients with 
anti-SC1 70 antibody might be expected to have ILD 
because they lack ACA, and indeed both such 
patients in the present study had restrictive lung 
disease. 
In contrast to ACA, anti-SC1 70 antibody status 
was not predictive of lung function in the study 
population. This contrasts with other reports of an 
association between anti-SC1 70 antibodies and inter- 
stitial lung disease (8,9). This discordance could be 
explained by the effects of anti-fibrotic therapy in 
those with anti-SC1 70 antibody, and the small 
number of patients with this antibody in the present 
study. In all but two of the patients receiving anti- 
fibrotic therapy in this cohort, D-penicillamine was 
employed. Two patients who received extracorporeal 
photochemotherapy had diffuse SSc and lacked Scl 
70 and ACA antibodies. Anti-fibrotic therapy, 
D-penicillamine in particular, has been associated 
with improvement in DLCO, and prolonged survival, 
in addition to improvement in skin sclerosis (2629). 
Further study of larger populations with anti-SC1 70 
may be required, given the small number of patients 
in this report. 
Radiographic involvement was primarily in the 
lower lobes, as previously reported (31). However, 
among patients with interstitial disease noted on 
chest radiograph, three patients (14%) had isolated 
mid-lung or upper lobe abnormalities. This obser- 
vation suggests that abnormalities in the mid and 
upper lung zones may be seen in this disease and 
should not be dismissed as unrelated parenchymal 
abnormalities. 
The observation that the presence of ACA has 
greater predictive value for interstitial lung involve- 
ment in SSc than the extent of skin involvement 
highlights the complex immunopathogenesis of SSc. 
Moreover, it is remarkable that the presence of an 
autoantibody appears to be protective against the 
development of lung fibrosis as the authors are aware 
of no other such autoantibody. One hypothesis for 
the protective effect of ACA could be its association 
with specific major histocompatibility complex anti- 
gens. Pulmonary fibrosis in SSc has been shown to be 
strongly associated with DR52a haplotype (32). This 
haplotype has been shown to be associated with the 
anti-SC1 70 antibody. In contrast, ACA is associated 
with DRl and DR4 haplotypes which may be pro- 
tective against the development of pulmonary fibro- 
sis. It is not surprising that the autoantibodies 
discussed here, as well as others, such as antihistone 
antibodies, are the focus of recent investigations into 
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the pathogenesis of SSc (33,34). Studies of potential 
differences in the regulation of lung tissue injury and 
repair in patients with and without ACA may shed 
light on the pathogenesis of pulmonary inflammation 
and fibrosis in SSc. 
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